Gilead(US:GILD)2024-08-08 21:37Financial Performance - Total product sales excluding Veklury increased by 6% year-over-year (YoY) to $6.7 billion[8] - HIV product sales increased by 3% YoY to $4.7 billion[14] - Oncology product sales increased by 15% YoY to $841 million[8] - Biktarvy sales increased by 8% YoY to $3.2 billion[8] - Trodelvy sales increased by 23% YoY[8] - Cell Therapy sales increased by 11% YoY[8] - Veklury sales decreased by 16% YoY to $214 million[14] HIV Pipeline and Prevention - Lenacapavir demonstrated 100% efficacy in HIV prevention in PURPOSE 1 trial[8, 37] - Biktarvy holds over 49% U S market share[20] - Descovy holds over 40% U S market share in PrEP[20] Oncology Pipeline - Anito-cel tech/IND transfer complete, with Ph2 iMMagine-1 update and Ph3 iMMagine-3 trial FPI estimated in 2H24[8] - Updated Ph2 EVOKE-02 data supports Ph3 EVOKE-03 trial in 1L PD-L1 high mNSCLC[8]